Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To explore the potential efficacy of 18F-FAPI-04 PET/CT for PDAC tumour staging and compare the results with those obtained using 18F-FDG PET/CT.
Accurate diagnosis and staging are crucial for selecting treatment for patients with pancreatic ductal adenocarcinoma (PDAC). The desmoplastic responses associated with PDAC are often characterised by hypometabolism. Here we investigated 18F-fibroblast activation protein inhibitor (18F-FAPI-04) positron emission tomography/computed tomography (PET/CT) in evaluation of PDAC, and compared the findings with those obtained using (18F)-fluorodeoxyglucose (18F-FDG).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental | Experimental | Patients underwent both 18F-FDG PET/CT and 18F-FDG PET/CT scan |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 18F-FAPI | Drug | Intravenous injection of one dosage of 18F-FAPI. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic value | Sensitivity and Specificity of 18F-FAPI PET/CT for diagnosis and staging in comparison with 18F-FDG PET/CT | 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT) |
| Maximum standardized uptake value | SUVmax of 18F-FAPI PET/CT for lesions in comparison with 18F-FDG PET/CT | 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT) |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic efficacy for primary lesions | Sensitivity, specificity, accuracy of 18F-FAPI PET/CT for primary lesions in comparison with 18F-FDG PET/CT | 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT) |
| SUVmax for primary lesions |
Not provided
Inclusion Criteria:
patients who were suspected to have PDAC by radiological imaging patients who underwent paired 18F-FAPI-04 PET/CT and 18F-FDG PET/CT for metastasis screening, recurrence confirmation, or tumour staging patients who were willing to participate in clinical trials and signed an informed consent form.
Exclusion Criteria:
patients with a history of severe contrast allergy pregnant patients patients who were not pathologically diagnosed as showing PDAC.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tingbo Liang, Ph.D., M.D. | Zhejiang University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| the First Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou | Zhejiang | 310003 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38176719 | Derived | Li X, Lu N, Lin L, Chen Y, Yang S, Wang H, Liu X, Wu C, Xue X, Su X, Bai X, Liang T. 18F-FAPI-04 Outperforms 18F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma. J Nucl Med. 2024 Feb 1;65(2):206-212. doi: 10.2967/jnumed.123.266283. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004194 | Disease |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D019788 | Fluorodeoxyglucose F18 |
| ID | Term |
|---|---|
| D003847 | Deoxyglucose |
| D003837 | Deoxy Sugars |
| D002241 | Carbohydrates |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 18F-FDG | Drug | Intravenous injection of one dosage of 18F-FDG. |
|
|
SUVmax of 18F-FAPI PET/CT for primary lesions in comparison with 18F-FDG PET/CT |
| 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT) |
| SUVmax for lymph node | SUVmax of 18F-FAPI PET/CT for lymph node in comparison with 18F-FDG PET/CT | 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT) |
| SUVmax for distant metastasis | SUVmax of 18F-FAPI PET/CT for distant metastasis in comparison with 18F-FDG PET/CT | 1 day (At the time the patient has underwent both 18F-FAPI and 18F-FDG PET/CT) |
| Correlation between the SUVmax of 18F-FAPI and 18F-FDG uptake in patients with different treatment response | The correlation of SUVmax and treatment response | at least 2 months after treatment |